Related Experiment Video
Updated: May 25, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Atrial fibrillation and cardiembolic stroke. Treatment and issue in acute phase]
1Cerebrovascular Medicine, Kyushu Medical Center.
Insights
For acute cardioembolic stroke, consider intravenous thrombolysis with rt-PA, brain protection, and edema treatment. Immediate anticoagulation requires careful risk-benefit assessment, with heparin often used alongside warfarin but not typically with dabigatran.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Context:
- Acute cardioembolic stroke management requires a multi-faceted approach.
- Timely interventions are critical in the acute phase of stroke.
Purpose:
- To outline current therapeutic considerations for acute cardioembolic stroke.
- To discuss the role and timing of thrombolysis and anticoagulation.
Summary:
- Recommended treatments include rt-PA intravenous thrombolysis (within 3 hours if eligible), intra-arterial thrombolysis, neuroprotection with edaravone, and glycerol for cerebral edema.
- Immediate anticoagulation efficacy is not fully established and necessitates individual risk-benefit evaluation.
- When initiating warfarin, concurrent heparin is advised until therapeutic anticoagulation is achieved; dabigatran, having rapid action, often obviates the need for heparin.
Impact:
- Provides a concise overview of acute cardioembolic stroke treatment options.
- Highlights the nuanced decision-making process for anticoagulation in this patient group.
- Informs clinical practice regarding the use of thrombolytics and anticoagulants.
Abstract:
In addition to the general treatment, rt-PA intravenous thrombolysis, intraarterial thrombolysis, brain protecting therapy with edaravone, glycerol treatment against brain edema, and immediate anticoagulant therapy should be considered in acute phase of cardioembolic stroke. The rt-PA intravenous thrombolysis within three hours of onset is recommended in acute stroke patients who meet criteria for the therapy. Because the efficacy of immediate anticoagulation in acute cardioembolic stroke has not been established yet, it depends on balance of risk and benefit in each patient whether immediate anticoagulant therapy should be commenced or not. When we start anticoagulation with warfarin, heparin which has rapid action should be administered at the same time until PT-INR increases into therapeutic range to avoid acute recurrent stroke. However when we start with dabigatran which has rapid action, heparin is usually not required.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Acute Coronary Syndrome IV: Interprofessional Care
Ischemic Stroke l: Introduction
